查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010013

體外診斷市場：2026年至2032年全球市場預測，依產品、檢測類型、檢體類型、應用、最終用戶和患者群體分類

In-Vitro Diagnostics Market by Offering, Test Type, Specimen, Application, End User, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，體外診斷市場價值將達到 1,099.9 億美元，到 2026 年將成長至 1,173.1 億美元，到 2032 年將達到 1,751.4 億美元，複合年成長率為 6.87%。

主要市場統計數據
基準年 2025 1099.9億美元
預計年份：2026年 1173.1億美元
預測年份 2032 1751.4億美元
複合年成長率 (%) 6.87%

為現代體外診斷市場的領導者提供策略展望，以技術融合、臨床需求和營運重點為框架。

體外診斷處於臨床需求、技術創新和醫療保健系統經濟的交匯點，需要清晰且可操作的見解，才能幫助相關人員駕馭這一快速發展的領域。本報告首先將診斷置於現代臨床工作流程中，重點在於闡述儀器、檢測設計和數位分析的進展如何重塑診斷流程。隨後，報告追蹤了這些進步在檢查室、醫院和即時檢驗 (POC) 環境中的實際影響，揭示了營運壓力和監管預期如何影響引進週期和投資決策。

自動化、數位分析、即時護理的擴展以及不斷變化的法規如何全面重塑診斷開發、交付和營運策略。

在診斷領域，一系列變革正在發生，它們正在重新定義整個醫療保健系統中診斷方法的開發、檢驗和實施方式。自動化和定序技術的進步提高了處理能力，並擴展了可進行的檢測範圍。同時，診斷軟體與雲端原生分析的融合，正在將原始數據轉化為可操作的臨床見解。因此，決策者們不得不權衡傳統的資本密集型檢查室投資與強調敏捷性和持續改進的新型「軟體優先」模式。

關稅趨勢的變化迫使診斷服務提供者和買家重新設計其採購、物流和商業化策略，以維持供應的連續性和價格競爭力。

2025年美國關稅環境對整個診斷供應鏈、採購定價和籌資策略都帶來了巨大壓力，迫使相關人員重新評估與供應商的關係以及對零件的依賴程度。進口試劑、耗材和某些儀器組件的關稅導致成本增加，促使各方更加重視供應鏈透明度和多元化採購策略。採購團隊加快了二級供應商的認證速度，供應商也調整了經營模式，透過本地生產、重新談判合約條款或重新設計產品來應對不斷上漲的接收成本，從而減少對受關稅影響的原料的依賴。

透過進行綜合細分分析，識別產品類型、測試方法、檢體考量、臨床應用和最終用戶趨勢的交集，可以創造策略機會。

基於產品、測試、檢體、應用和最終用戶等關鍵細分框架進行分析，能夠最清楚地洞察需求促進因素和市場採納模式。市場趨勢的研究涵蓋了儀器、試劑/試劑盒和軟體/服務等產品類型。儀器進一步細分為分析儀器、自動化系統和定序儀，而軟體/服務則分為校準服務、諮詢服務、診斷軟體和維護服務。這種觀點揭示了資本設備生命週期、耗材依賴和業務收益如何相互作用，從而影響供應商策略和客戶採購偏好。

世界各地不同的管理體制、醫療基礎設施和採購實務如何影響診斷技術的應用模式和商業策略？

區域趨勢對全球各大區域的競爭策略和部署重點產生了不同的影響。在美洲，成熟的檢查室網路、大規模私人保險公司以及對以價值為導向的醫療保健模式的高度重視（這種模式重視診斷準確性和更快的回應速度）共同推動了市場需求。因此，在該地區運營的供應商通常優先考慮高通量儀器、全面的試劑組合以及與集中式實驗室資訊系統的兼容性，以滿足大規模醫院網路和參考實驗室的需求。

在臨床環境中，競爭差異化越來越依賴整合的產品生態系統、策略夥伴關係和服務主導的經營模式，以確保信任和永續的收入。

在這個領域，競爭優勢越來越取決於企業能否將卓越的技術、服務能力和策略夥伴關係融會貫通。主要企業透過整合高效能儀器、專有試劑和強大的軟體生態系統，打造整合解決方案，從而實現數據驅動的洞察，以此脫穎而出。其他企業則專注於細分領域，提供一流的診斷方法和專為即時檢測環境最佳化的緊湊型平台，同時利用臨床夥伴關係關係來檢驗產品性能並加速其在臨床環境中的部署。

要將技術創新轉化為永續的商業性優勢，我們需要採取切實可行的策略行動，協調平台設計、監管合規、供應鏈彈性和服務擴展。

產業領導企業應採取一系列協調一致的措施，將研發、監管策略和商業性執行結合，以建立長期韌性，同時滿足短期臨床需求。首先，優先建構模組化平台架構，該架構既支援集中式高通量分析，也支援分散式即時檢測部署，從而靈活服務於不同的客戶群。其次，尤其對於軟體主導的診斷產品，應從產品開發的早期階段就投資於監管準備工作，以縮短認證時間並最大限度地降低跨轄區適應成本。第三，透過供應商多元化、區域製造夥伴關係和策略性庫存管理來增強供應鏈韌性，從而抵禦關稅和物流波動的影響。

為了確保獲得可靠且可操作的見解，我們採用了嚴格的混合方法研究途徑，結合了與關鍵相關人員的訪談、技術檢驗和基於場景的壓力測試。

為確保可靠性和有效性，本分析所依據的研究採用了多層次的調查方法，整合了訪談、技術文件審查和結構化檢驗。訪談包括對實驗室經理、採購經理、臨床專家以及儀器和試劑供應商的高階主管進行詳細訪談，以了解目前的決策標準、營運限制和策略重點。此外，還對監管指南、臨床文獻和產品技術規範進行了系統性審查，以檢驗性能聲明並梳理監管路徑，從而補充了上述定性資訊。

綜合策略結論強調了協調技術創新、臨床證據和營運韌性的重要性，以確保長期部署和商業性成功。

如果產業相關人員能夠將技術創新與切實可行的商業和營運策略相結合，體外診斷仍將是改善病患預後和最佳化診療路徑的重要策略工具。本報告的綜合分析表明，那些將平台柔軟性、可靠的檢驗證據和穩健的供應鏈模式融入其價值提案的組織才能取得成功。同樣重要的是，企業還需具備將技術差異化轉化為服務模式的能力，從而深化客戶關係並提供可預測的收入來源。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 體外診斷市場：依產品/服務分類

  • 裝置
    • 分析器
    • 自動化系統
    • 定序裝置
  • 試劑和試劑盒
  • 服務
    • 安裝和驗證服務
    • 培訓和諮詢服務
    • 維護和支援服務
  • 軟體和資訊系統
    • 檢查室資訊系統
    • 數據分析與解釋軟體

第9章 體外診斷市場（依檢測類型分類）

  • 臨床化學
    • 血液分析
    • 電解質面板
    • 肝功能檢查
    • 甲狀腺功能檢查
    • 尿液檢查
  • 血液學
  • 免疫檢測
  • 微生物學
  • 分子診斷

第10章檢體類型分類的體外診斷試劑市場

  • 血液、血清和血漿
  • 唾液
  • 組織樣本
  • 尿

第11章 體外診斷市場：依應用分類

  • 自體免疫疾病
  • 癌症篩檢
  • 心臟監測
  • 糖尿病管理
  • 基因檢測
  • 傳染病檢查

第12章 體外診斷市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢查室
  • 醫院
  • 即時檢測中心

第13章 依病患類型分類的體外診斷市場

  • 成人
  • 兒童

第14章 體外診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 體外診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 體外診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國體外診斷市場

第18章：中國體外診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agappe Diagnostics Ltd.
  • Agilent Technologies, Inc.
  • ARKRAY Inc.
  • Asahi Kasei Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Edan Instruments, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • HiMedia Laboratories Pvt. Ltd.
  • Hitachi High-Tech Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • J Mitra & Co. Pvt. Ltd.
  • KAINOS Laboratories, Inc.
  • Kyowa Medex Co., Ltd.
  • Meril Diagnostics Pvt. Ltd.
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Seegene, Inc.
  • Sekisui Medical Co., Ltd.
  • Shanghai Kehua Bio-engineering Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • Sino Biopharmaceutical Limited
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Transasia Bio-Medicals Ltd.
  • Werfen, SA
  • Zhejiang Orient Gene Biotech Co.,Ltd.
Product Code: MRR-434CCDA04D33

The In-Vitro Diagnostics Market was valued at USD 109.99 billion in 2025 and is projected to grow to USD 117.31 billion in 2026, with a CAGR of 6.87%, reaching USD 175.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 109.99 billion
Estimated Year [2026] USD 117.31 billion
Forecast Year [2032] USD 175.14 billion
CAGR (%) 6.87%

A strategic orientation to the contemporary in-vitro diagnostics environment that frames technological convergence, clinical imperatives, and operational priorities for leaders

In-vitro diagnostics sit at the intersection of clinical need, technological innovation, and health-system economics, and stakeholders require clear, actionable intelligence to navigate this rapidly evolving field. The report opens by situating diagnostics within contemporary clinical workflows, highlighting how advances in instrumentation, assay design, and digital analytics are reshaping diagnostic pathways. It then traces the practical implications for laboratories, hospitals, and point-of-care settings, acknowledging how operational pressures and regulatory expectations influence adoption cycles and investment decisions.

Moving from context to consequence, the introduction frames the core vectors of change-technology convergence, shifting care delivery models, and supply chain recalibration-and explains why these vectors matter to executive teams, clinical leaders, and technology vendors. It emphasizes the need for strategies that balance clinical performance with cost-efficiency and regulatory compliance, while also preserving the agility to adapt to emergent public health demands. The narrative closes by outlining the structure of the analysis that follows, clarifying how subsequent sections translate complex dynamics into prioritized insights and practical recommendations for stakeholders seeking competitive and clinical advantage.

How automation, digital analytics, point-of-care expansion, and regulatory evolution are collectively reshaping diagnostic development, delivery, and operational strategy

The diagnostics landscape is experiencing a series of transformative shifts that are redefining how diagnostics are developed, validated, and deployed across care settings. Advances in automation and sequencing technologies are enabling higher throughput and broader test menus, while the integration of diagnostic software and cloud-native analytics is turning raw assay outputs into actionable clinical intelligence. As a result, decision-makers must reconcile traditional capital-intensive laboratory investments with emerging software-first models that emphasize agility and continuous improvement.

Concurrently, point-of-care testing is moving beyond rapid antigen models to embrace more sophisticated analyzers and compact molecular platforms, shifting diagnostic capacity closer to patients and accelerating clinical decision timelines. Regulatory frameworks are also evolving to address software as a medical device and to streamline pathways for companion diagnostics, creating both opportunities and compliance complexities. Moreover, supply chain resilience and the reshoring of critical components are now strategic priorities, informing procurement criteria and partnership strategies. Taken together, these shifts are prompting a re-evaluation of product road maps, commercialization strategies, and clinical validation approaches, and they demand integrated responses that align commercial, clinical, and operational objectives.

Evolving tariff dynamics have forced diagnostic providers and buyers to redesign sourcing, logistics, and commercialization strategies to preserve supply continuity and competitive pricing

The U.S. tariff environment in 2025 introduced substantive pressures across diagnostic supply chains, procurement pricing, and sourcing strategies, compelling stakeholders to reassess vendor relationships and component dependencies. Tariff-driven cost increases for imported reagents, consumables, and select instrumentation components have translated into sharper prioritization of supply chain transparency and multi-sourcing strategies. Procurement teams have accelerated qualification of secondary suppliers, and vendors have adjusted commercial models to accommodate increased landed costs through localized manufacturing, renegotiated terms, or product redesign that lowers exposure to tariffed inputs.

In parallel, regulatory and customs compliance burdens have grown, prompting greater emphasis on documentation, classification accuracy, and cross-border logistics planning. Clinical laboratories and distributors have responded by enhancing inventory management and by negotiating longer-term contracts that provide price predictability and supply continuity. Importantly, the tariff landscape has stimulated strategic investment in regional manufacturing hubs and collaborative alliances aimed at reducing reliance on single-country sourcing. Consequently, tariff dynamics are no longer a short-term procurement complication but an enduring factor shaping capital allocation, pricing strategies, and partnership models across the diagnostics value chain.

Integrated segmentation analysis revealing where product types, test modalities, specimen considerations, clinical applications, and end-user dynamics intersect to create strategic opportunities

Insight into demand drivers and adoption patterns emerges most clearly when analysis is structured around the primary segmentation frameworks used by product, test, specimen, application, and end-user categories. Based on product type, the landscape is studied across Instruments, Reagents & Kits, and Software & Services, with Instruments further analyzed through Analyzers, Automation Systems, and Sequencing Instruments, and Software & Services further divided into Calibration Services, Consultancy Services, Diagnostic Software, and Maintenance Services. This lens reveals how capital equipment lifecycles, consumable dependencies, and service revenues interact to shape vendor strategies and client procurement preferences.

Based on test type, the study examines Clinical Chemistry, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics, with Clinical Chemistry further detailed across Blood Analysis, Electrolyte Panel, Liver Panel, Thyroid Function Panel, and Urine Analysis. This taxonomy highlights where clinical demand is concentrated and where innovation-such as multiplex assays or digital interpretation-creates differentiation. Based on specimen, the analysis covers Blood, Serum & Plasma, Saliva, Tissue Samples, and Urine, indicating how specimen type influences sample handling workflows and pre-analytical requirements. Based on application, the study considers Autoimmune Diseases, Cancer Detection, Cardiac Monitoring, Diabetes Management, Genetic Testing, and Infectious Disease Testing to clarify clinical use cases that drive adoption. Finally, based on end user, the work assesses Academic & Research Centers, Diagnostic Laboratories, Hospitals, and Point-Of-Care Testing Centers to illuminate procurement cycles, reimbursement sensitivities, and operational readiness. By integrating these segmentation dimensions, the analysis surfaces which product-test-specimen-application-end user combinations present the clearest pathways for product differentiation, clinical validation prioritization, and tailored go-to-market execution.

How differing regulatory regimes, healthcare infrastructures, and procurement behaviors across global regions are influencing diagnostic adoption patterns and commercial strategies

Regional dynamics are shaping competitive strategies and deployment priorities in distinctly different ways across the world's major geographies. In the Americas, demand is driven by a combination of mature laboratory networks, large private payers, and a strong emphasis on value-based care models that reward diagnostic accuracy and time-to-result improvements. Consequently, suppliers operating in this region often emphasize high-throughput instruments, comprehensive reagent portfolios, and compatibility with centralized laboratory information systems to meet the needs of large hospital networks and reference laboratories.

In Europe, Middle East & Africa, regulatory harmonization initiatives and heterogeneous reimbursement environments produce a fragmented adoption landscape. Manufacturers and distributors must navigate diverse national regulatory requirements while adapting pricing and service models to varied procurement practices. Strategic partnerships and localized service capabilities are therefore critical to achieving traction. In Asia-Pacific, rapid expansion of diagnostic capacity, significant public health investment, and the proliferation of private healthcare providers are driving demand for scalable automation, molecular testing platforms, and decentralized testing solutions. Across these regions, differences in supply chain maturity, regulatory timelines, and clinical priorities inform how vendors sequence market entry, allocate resources for clinical validation, and structure commercial partnerships.

Competitive differentiation increasingly depends on integrated product ecosystems, strategic partnerships, and service-led business models that secure clinical trust and recurring revenue

Competitive positioning in this sector is increasingly determined by a company's ability to combine technical excellence with service capabilities and strategic partnerships. Leading firms differentiate through integrated solutions that couple high-performance instruments with proprietary reagents and robust software ecosystems that enable data-driven insights. Other players focus on niche specialization, providing best-in-class assays or compact platforms tailored for point-of-care environments, and they leverage clinical partnerships to validate performance and accelerate clinical adoption.

Partnership strategies are also central to growth, with collaborations spanning co-development, distribution alliances, and service networks that expand geographic reach. Meanwhile, aftermarket services such as calibration, maintenance, and consultancy not only create recurring revenue streams but also deepen customer relationships and reduce churn. New entrants tend to compete on speed of innovation and focused clinical use cases, while incumbent vendors emphasize scale, regulatory experience, and established relationships with health systems. Taken together, these dynamics underscore the importance of aligning product road maps, commercial models, and service delivery to capture clinical trust and long-term contracts.

Practical strategic actions to align platform design, regulatory preparedness, supply resilience, and service expansion to convert technical innovation into enduring commercial advantage

Industry leaders should adopt a coordinated set of actions that align R&D, regulatory strategy, and commercial execution to capture near-term clinical needs while building long-term resilience. First, prioritize modular platform architectures that support both centralized high-throughput analytics and decentralized point-of-care deployments, enabling flexible responses to diverse customer segments. Second, invest in regulatory-readiness early in product development, particularly for software-driven diagnostics, to reduce time-to-qualification and to minimize adaptation costs across jurisdictions. Third, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and strategic inventory management to buffer against tariff and logistics volatility.

Furthermore, expand service portfolios to include calibration, maintenance, and consultancy offerings that embed products within customer workflows and create recurring revenue. Leverage real-world performance data to build clinical and economic evidence packages that support reimbursement discussions and drive clinician confidence. Finally, pursue selective partnerships with clinical networks and academic centers to accelerate validation and to demonstrate clinical utility in high-impact applications. These combined actions will help organizations convert technical capability into enduring commercial advantage while mitigating regulatory and supply-side risks.

A rigorous mixed-methods research approach combining primary stakeholder interviews, technical validation, and scenario stress-testing to ensure credible and actionable insights

The research underpinning this analysis employed a layered methodology that integrates primary interviews, technical document review, and structured triangulation to ensure robustness and relevance. Primary research included in-depth interviews with laboratory directors, procurement leads, clinical specialists, and senior executives from equipment and reagent suppliers to capture current decision criteria, operational constraints, and strategic priorities. These qualitative inputs were complemented by systematic review of regulatory guidance, clinical literature, and product technical specifications to validate performance claims and to map regulatory pathways.

Quantitative validation was achieved through cross-referencing procurement patterns, device filings, and published clinical evaluation studies, enabling a consolidated view of adoption drivers and technical trade-offs. Throughout the process, findings were stress-tested through advisor reviews and scenario analysis to identify sensitivities and to surface practical mitigation approaches. Data governance practices ensured traceability and confidentiality of primary inputs, and methodological limitations were identified explicitly to contextualize interpretation. This rigorous, mixed-methods approach supports credible, actionable insights that are directly relevant to commercial planning and clinical strategy.

Consolidated strategic conclusions emphasizing the imperative to align technological innovation, clinical evidence, and operational resilience to secure long-term adoption and commercial success

In-vitro diagnostics are poised to remain a strategic lever for improving patient outcomes and for optimizing care pathways, provided that industry actors align technological innovation with pragmatic commercial and operational strategies. The synthesis presented here emphasizes that success will come to those organizations that integrate platform flexibility, robust validation evidence, and resilient supply chain models into their value propositions. Equally important is the ability to translate technical differentiation into service models that deepen customer relationships and provide predictable revenue streams.

Looking ahead, leaders must remain vigilant to regulatory evolution, to shifting care delivery patterns that favor decentralization, and to macroeconomic forces that affect sourcing and pricing. By prioritizing interoperability, evidence generation, and regional adaptability, stakeholders can convert complexity into competitive advantage. Ultimately, the capacity to synthesize clinical relevance with operational feasibility will determine which technologies achieve lasting clinical adoption and commercial traction.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Market, by Offering

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Automation Systems
    • 8.1.3. Sequencing Instrument
  • 8.2. Reagents & Kits
  • 8.3. Services
    • 8.3.1. Installation & Validation Services
    • 8.3.2. Training & Consulting Services
    • 8.3.3. Maintenance & Support Services
  • 8.4. Software & Informatics
    • 8.4.1. Laboratory Information Systems
    • 8.4.2. Data Analytics & Interpretation Software

9. In-Vitro Diagnostics Market, by Test Type

  • 9.1. Clinical Chemistry
    • 9.1.1. Blood Analysis
    • 9.1.2. Electrolyte Panel
    • 9.1.3. Liver Panel
    • 9.1.4. Thyroid Function Panel
    • 9.1.5. Urine Analysis
  • 9.2. Hematology
  • 9.3. Immunoassays
  • 9.4. Microbiology
  • 9.5. Molecular Diagnostics

10. In-Vitro Diagnostics Market, by Specimen

  • 10.1. Blood, Serum & Plasma
  • 10.2. Saliva
  • 10.3. Tissue Samples
  • 10.4. Urine

11. In-Vitro Diagnostics Market, by Application

  • 11.1. Autoimmune Diseases
  • 11.2. Cancer Detection
  • 11.3. Cardiac Monitoring
  • 11.4. Diabetes Management
  • 11.5. Genetic Testing
  • 11.6. Infectious Disease Testing

12. In-Vitro Diagnostics Market, by End User

  • 12.1. Academic & Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Point-Of-Care Testing Centers

13. In-Vitro Diagnostics Market, by Patient Type

  • 13.1. Adults
  • 13.2. Pediatrics

14. In-Vitro Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In-Vitro Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In-Vitro Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States In-Vitro Diagnostics Market

18. China In-Vitro Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agappe Diagnostics Ltd.
  • 19.7. Agilent Technologies, Inc.
  • 19.8. ARKRAY Inc.
  • 19.9. Asahi Kasei Corporation
  • 19.10. Becton, Dickinson and Company
  • 19.11. Bio-Rad Laboratories, Inc.
  • 19.12. bioMerieux SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. Edan Instruments, Inc.
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Grifols S.A.
  • 19.18. HiMedia Laboratories Pvt. Ltd.
  • 19.19. Hitachi High-Tech Corporation
  • 19.20. Hologic, Inc.
  • 19.21. Illumina, Inc.
  • 19.22. J Mitra & Co. Pvt. Ltd.
  • 19.23. KAINOS Laboratories, Inc.
  • 19.24. Kyowa Medex Co., Ltd.
  • 19.25. Meril Diagnostics Pvt. Ltd.
  • 19.26. Nihon Kohden Corporation
  • 19.27. PerkinElmer, Inc.
  • 19.28. QIAGEN N.V.
  • 19.29. QuidelOrtho Corporation
  • 19.30. Revvity, Inc.
  • 19.31. Seegene, Inc.
  • 19.32. Sekisui Medical Co., Ltd.
  • 19.33. Shanghai Kehua Bio-engineering Co., Ltd.
  • 19.34. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 19.35. Siemens AG
  • 19.36. Sino Biopharmaceutical Limited
  • 19.37. Sysmex Corporation
  • 19.38. Thermo Fisher Scientific, Inc.
  • 19.39. Tosoh Corporation
  • 19.40. Transasia Bio-Medicals Ltd.
  • 19.41. Werfen, S.A.
  • 19.42. Zhejiang Orient Gene Biotech Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SEQUENCING INSTRUMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTALLATION & VALIDATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA ANALYTICS & INTERPRETATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 229. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GCC IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 262. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 268. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 279. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)